Patent Yard Sign in
Expired Canadian patentCanada

Methods of inhibiting vascular permeability and apoptosis

CA 2529318 C · Owner: Hla, Timothy · Inventors: Paik, Ji-Hye; Hla, Timothy; Claffey, Kevin P.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated froms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis and , for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis and , for the growth of …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed June 18, 2004 and granted September 17, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 18, 2024.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 18, 2026.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJune 18, 2004
GrantedSeptember 17, 2013
Term endedJune 18, 2024
Patent numberCA 2529318 C
Classification (IPC)A61K31/13 +2 more

Timeline

Timeline From CIPO dates

2005200720092011201320152017201920212023Application filedJune 18, 2004Patent grantedSep 17, 2013Term endedJune 18, 2024

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.